Allogene Therapeutics Inc’s filing revealed that its Officer Roberts Zachary acquired Company’s shares for reported $32014.0 on Feb 03 ’25. In the deal valued at $1.70 per share,18,832 shares were bought.
Then, Chang David D bought 46,003 shares, generating $77,446 in total proceeds.
Before that, Douglas Earl Martin bought 6,404 shares. Allogene Therapeutics Inc shares valued at $10,951 were divested by the Officer at a price of $1.71 per share.
A number of analysts have revised their coverage, including Piper Sandler’s analysts, who began to cover the stock in late May with a ‘”an Overweight”‘ rating. JMP Securities also remained covering ALLO and has decreased its forecast on January 05, 2024 with a “Mkt perform” recommendation from previously “Mkt outperform” rating. Guggenheim revised its rating on January 05, 2024. It rated ALLO as “a Neutral” which previously was an “a Buy”.
Price Performance Review of ALLO
On Tuesday, Allogene Therapeutics Inc [NASDAQ:ALLO] saw its stock fall -2.99% to $1.62. Over the last five days, the stock has lost -16.06%. Allogene Therapeutics Inc shares have fallen nearly -23.94% since the year began. Nevertheless, the stocks have fallen -56.33% over the past one year. While a 52-week high of $5.78 was reached on 01/07/25, a 52-week low of $1.65 was recorded on 02/04/25. SMA at 50 days reached $2.0690, while 200 days put it at $2.5309.
Levels Of Support And Resistance For ALLO Stock
The 24-hour chart illustrates a support level at 1.5767, which if violated will result in even more drops to 1.5333. On the upside, there is a resistance level at 1.6917. A further resistance level may holdings at 1.7633. The Relative Strength Index (RSI) on the 14-day chart is 32.70, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.1476, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 97.03%. Stochastics %K at 4.46% indicates the stock is a buying.
How much short interest is there in Allogene Therapeutics Inc?
A steep rise in short interest was recorded in Allogene Therapeutics Inc stocks on 2025-01-15, dropping by 19694.0 shares to a total of 32.35 million shares. Yahoo Finance data shows the prior-month short interest on 2024-12-13 was 32.37 million shares. There was a decline of -0.06%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on December 08, 2023 when Citigroup began covering the stock and recommended ‘”a Buy”‘ rating along with a $7 price target.
